8-K

PURE BIOSCIENCE, INC.

Dated: December 31, 2013

/s/ Peter C. Wulff

Peter C. Wulff

Chief Financial Officer, Chief Operating Officer

and Corporate Secretary

0001193125-13-488605.txt : 20131231 0001193125-13-488605.hdr.sgml : 20131231 20131231170859 ACCESSION NUMBER: 0001193125-13-488605 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131223 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20131231 DATE AS OF CHANGE: 20131231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 131306056 BUSINESS ADDRESS: STREET 1: 1725 GILLESPIE WAY CITY: EL CAJON STATE: CA ZIP: 92020 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 1725 GILLESPIE WAY CITY: EL CAJON STATE: CA ZIP: 92020 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 8-K 1 d652232d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2013

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-14468	33-0530289
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1725 Gillespie Way El Cajon, California		92020
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01.

Entry into a Material Definitive Agreement.

PURE Bioscience, Inc. (the “Company”) announced that it has entered into a promissory note payoff agreement (the “Payoff Agreement”) with Morrison & Foerster LLP (“Morrison”). Under the Payoff Agreement, the Company paid $500,000 to Morrison to extinguish $1,125,000 in unsecured debt owed to Morrison under a promissory note, dated January 25, 2013 (the “Note”). The Company has no further obligations or liability under the Note. The financial impact of the Payoff Agreement will be reflected in the Company’s quarterly period ended January 31, 2014.

The foregoing description of the Payoff Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Payoff Agreement, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the period ending on January 31, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.